Clinical Trials Logo

Head and Neck Neoplasms clinical trials

View clinical trials related to Head and Neck Neoplasms.

Filter by:

NCT ID: NCT02984033 Withdrawn - Quality of Life Clinical Trials

Quality of Life and Psycological Evaluation of Patients Affected by Head and Neck Cancer

Start date: November 2016
Phase:
Study type: Observational

The prospective trial is to describe the quality of life and psychological effects in patients with head and neck tumor receiving curative intent treatment

NCT ID: NCT02982746 Completed - Clinical trials for Health Related Quality of Life

Can a Person-centred-care Intervention Improve Health-related Quality of Life in Patients With Head and Neck Cancer

Start date: April 2012
Phase: N/A
Study type: Interventional

At all of the follow-ups, including the worst period (between four and ten weeks), the intervention group reported higher scores than the control group, suggesting in this RCT that adopting the person-centred-care concept was a promising way to improve function and wellbeing in patients with HNC.

NCT ID: NCT02980653 Recruiting - Clinical trials for Head and Neck Cancer

Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT

Start date: May 2015
Phase: Phase 2
Study type: Interventional

Primary Objective: To evaluate the population prevalence of critical body weight loss ( more than 5% from baseline) in patients with Head and Neck cancer. Secondary Objectives: To evaluate the impact of appetite, and performance status; To evaluate the change of quality of life (QoL); To evaluate the incidence of infection and hospitalization; To evaluate the safety profiles

NCT ID: NCT02980601 Terminated - Clinical trials for Head and Neck Cancer

The Use of Integra in Coverage of Radial Forearm Free Flap Donor Site Defect

Start date: November 2015
Phase: N/A
Study type: Interventional

The purpose of this research study is to compare the forearm free flap of patients with a traditional split thickness skin graft and those repaired with Integra (a skin substitute that helps to provide wound closure) and a split thickness skin graft. The study team will be looking at the subject's satisfaction with how the skin graft site looks and how well the skin graft site is functioning.

NCT ID: NCT02979977 Recruiting - Clinical trials for Squamous Cell Cancers of the Head and Neck

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Start date: March 24, 2017
Phase: Phase 2
Study type: Interventional

This is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.

NCT ID: NCT02976883 Completed - Lung Cancer Clinical Trials

[18F]HX4 PET/CT Imaging for Detection of Hypoxia

OXYPET
Start date: March 31, 2015
Phase: Phase 2
Study type: Interventional

The aim of this study is to investigate the radiotracer [18F]HX4 for non-invasive detection of hypoxia in patients with head and neck, or lung cancer. Each participant will undergo a diagnostic [18F]HX4 PET/CT scan before beginning radiotherapy treatment. Patient follow up data will be collected from routine appointments, and analysed with the hypoxia scan results to assess whether [18F]HX4 PET/CT scanning can predict patient outcome from radiotherapy treatment.

NCT ID: NCT02975739 Terminated - Clinical trials for Head and Neck Neoplasms

Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors

HIT
Start date: September 2016
Phase: N/A
Study type: Interventional

The main objective is to establish the feasibility of 166-Holmium microspheres for intratumoral injections in oral squamous cell carcinoma (OSCC) of the tongue. Participants will receive intratumoral injections with a low radioactive 166-Holmium microspheres followed by surgical resection

NCT ID: NCT02972216 Completed - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy

Start date: November 2014
Phase: Phase 4
Study type: Observational

A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy

NCT ID: NCT02966509 Completed - Prostate Cancer Clinical Trials

Engagement of Patients With Advanced Cancer

EPAC
Start date: August 2013
Phase: N/A
Study type: Interventional

The Engagement of Patients with Advanced Cancer is an intervention that utilizes well-trained lay health coaches to engage patients and their families in goals of care and shared decision-making after a diagnosis of advanced cancer. Although lay health workers have never been tested in this role, we hypothesize that lay health workers can feasibly improve goals of care documentation and help to reduce unwanted healthcare utilization at the end of life for Veterans diagnosed with new advanced stages of cancer and those diagnosed with recurrent disease.

NCT ID: NCT02965001 Completed - Clinical trials for Head and Neck Cancer

Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer

Start date: November 2016
Phase: Phase 2
Study type: Interventional

Head and neck cancer (HNC) is the 6th most common cancer worldwide. In the last decade, there has been made substantial improvements in diagnosis, staging and treatment of HNC. The overall survival has improved, but for some subgroups it is unchanged and therefore new prognostic and surveillance methods are warranted. One of the hallmarks in cancer is the ability to invade the surrounding tissue and metastasize. Studies have shown that the urokinase proteolytic plasminogen activator (uPA) and its receptor (uPAR) are present at the very front of the invasive tumor and they are considered essential in cancer invasion and metastasis. Consequently, an uPAR-targeted tracer offers a very promising target for functional PET imaging and may be a stronger prognostic marker compared to routine FDG-PET/CT. We wish to clarify how uPAR-PET/CT correlate to patient outcome compared to routine FDG-PET/CT in patients with HNC in the pharynx, larynx and oral cavity, who are referred to curative intended radiotherapy. In this project all participants have an uPAR-PET/CT scan performed before initiation of the routine radiotherapy and the prognostic efficacy is determined by assessment of the recurrence rate and mortality at routine clinical follow-up.